References
- Papers of special note have been highlighted as:
- • of interest
- •• of considerable interest
- Barbato A. Schizophrenia and public health. Geneva: World Health Organization; 2014. p. 7–8.
- Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460–466.
- Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatr. 1996;153(3):321.
- Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114–126.
- Rao NP, Remington G. Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials. Expert Opin Investig Drugs. 2013;22(7):881–894.
- Clinical psychiatry news web page. Novel antipsychotic shows early promise. 2013 [cited 2015 Oct 12]. Available from: http://www.revivapharma.com/docs/Reviva_RP5063_Clinical_Psychiatry_News-5011July2013.pdf.
- Bugarski-Kirola D, Wang A, Abi-Saab D, et al. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia–Results from the CandleLyte study. Eur Neuropsychopharmacol. 2014;24(7):1024–1036.
- Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):605–614.
••The behavioral pharmacologic characteristics of Brexpiprazole are evaluated and compared with Aripiprazole and Risperidone in vivo
- Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.
- Clinical pharmacology of Brexpiprazole (Rexulti) [Internet]. 2015. [cited 2015 Oct 12]. Available from: http://www.rxlist.com/rexulti-drug/clinical-pharmacology.htm
- Higgins J, Green S. 9.5. 2 Identifying and measuring heterogeneity. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0, 1; 2008.
- A study evaluating the of OPC-34712 in subjects with normal hepatic function and hepatically impaired subjects [Internet]. 2015. [cited 2015 Oct 1]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01299454?term= brexpiprazole&type=Intr& cond=schizophrenia&rank=10§=X01256
••The only phase 1 study for Brexpiprazole
- Study to evaluate the efficacy, safety, and tolerability of Oral OPC-34712 and aripiprazole for treatment of acute schizophrenia (STEP 203) [Internet]. 2015. [cited 2015 Oct 1]. Available from: http://www.clinicaltrials.gov/ct2/show/results/NCT00905307?term=NCT00905307&rank=1
••Study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 and Aripiprazole for treatment of acute schizophrenia (STEP 203)
- McQuade R, Hobart M, Forbes R. A phase II trial assessing the efficacy and safety of OPC-34712 in the acute treatment of adult schizophrenia (Study 331-07-203). Poster Presentation, US Psychiatric Congress; 2011 Nov 7–11; Las Vegas, NV.
- Malla A, Sugaya K, Perry P, et al. The effect of brexpiprazole (OPC- 34712) in adult outpatients with early-episode schizophrenia: an exploratory study. Poster Presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL.
- Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) versus aripiprazole in adult patients with acute schizophrenia: an exploratory study. Poster Presentation, 70th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, SOBP; 2015 May 18; Toronto, ON.
- Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164(1):127–135.
••The published paper on BEACON trial
- Kane J, Skuban A, Youakim J, et al. A multicenter, randomized, controlled, phase III trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Neuropsychopharmacology. 2014;39:S357–S358. Poster Presentation.
- Duffy R, Ouyang J, Skuban A, et al. Analysis of efficacy and metabolic tolerability profile from two phase 3 studies of brexpiprazole in patients with acute schizophrenia. Schizophr Bull. 2015;41(Suppl. 1):S309. Poster Presentation.
- Skuban A, Correll CU, Kane JM, et al. Efficacy of brexpiprazole (OPC-34712) in acute schizophrenia: results of two pooled pivotal studies. Schizophr Bull. 2015;41(Suppl. 1):S333–S334. Poster Presentation.
- Eramo A, Skuban A, Ouyang J, et al. Incidence, onset, duration and sever- ity of akathisia with brexpiprazole (OPC-34712) in acute schizophrenia: a pooled analysis of two pivotal studies. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL.
- Marder SR, Skuban A, Ouyang J, et al. Efficacy of brexpiprazole (OPC-34712) on PANSS items and Marder Factor scores: a meta- analysis of two pivotal studies in schizophrenia. Poster presentation, 168th American Psychiatric Association Annual Meeting; 2015 May 16–20, Toronto, Canada.
- Correll CU, Skuban A, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(9):870–880.
••The published paper on VECTOR trial
- Correll C, Skuban A, Youakim J, et al. Brexpiprazole for the treatment of acute schizophrenia: a randomized, controlled trial. Poster presentation, Neuropsychopharmacology, 53rd Annual Meeting of the American College of Neuropsychopharmacology, ACNP; 2014 Dec 7–11; Phoenix, AZ; S474.
- Weiss C, Skuban A, Hobart M, et al. The metabolic tolerability profile of brexpiprazole (OPC-34712) in acute schizophrenia. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL; W89.
- Correll CU, Skuban A, Ouyang J, et al. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies. Schizophr Bull. 2015;41(Suppl. 1):S307–S307. Poster Presentation.
- Hobart M, Ouyang J, Forbes A. Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomized, double-blind, placebo-controlled study. Poster presentation, American Society of Clinical Psychopharmacology Annual Meeting; 2015 Jun 22–25; Miami, FL; W70.